Theo S Plantinga

6PUBLICATIONS

68CO-AUTHORS

Molecular targetsSolid tumoursTraditional Chinese medicine and treatmentsEpigenetics (incl. genome methylation and epigenomics)Haematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jun 30, 2026

Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability Tradeoffs.

|Oct 13, 2023

An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.

Jantine E Bakema, Marijke Stigter-van Walsum, Jeffrey R Harris

|Feb 17, 2022

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.

Alexander Muik, Elena Garralda, Isil Altintas

|Dec 17, 2021

Author Correction: GWAS of thyroid stimulating hormone highlights the pleiotropic effects and inverse association with thyroid cancer.

Wei Zhou, Ben Brumpton, Omer Kabil

|Aug 10, 2020

GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer.

Wei Zhou, Ben Brumpton, Omer Kabil

|Jan 27, 2017

Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages.

Rob J W Arts, Theo S Plantinga, Sander Tuit

Pageof 1

Frequent Collaborators

Esther C W Breij

Romana T Netea-Maier

Lars G Fritsche

Serena Sanna

Jonas B Nielsen

Morgan Oneka

Matthew Zawistowski

Wei Zhou

Ben Brumpton

Josh Weinstock

Frequent Collaborators

Esther C W Breij

Romana T Netea-Maier

Lars G Fritsche

Serena Sanna